Piclidenoson (CF101)

About can-fite-biopharma

Can Fite Biopharma's mission is to develop and commercialize novel, orally available therapeutics targeting the A3 adenosine receptor for oncology, inflammatory, and metabolic diseases. Its key achievements include establishing a robust pipeline with multiple Phase II/III candidates, securing significant out-licensing partnerships for its lead assets across major markets in Asia, Europe, and North America, and generating clinical proof-of-concept for its platform. The company's strategy is to advance its most promising programs through late-stage trials to achieve regulatory milestones, while continuing to monetize its pipeline through regional partnerships and non-dilutive funding to drive towards commercialization.

About can-fite-biopharma

Can Fite Biopharma's mission is to develop and commercialize novel, orally available therapeutics targeting the A3 adenosine receptor for oncology, inflammatory, and metabolic diseases. Its key achievements include establishing a robust pipeline with multiple Phase II/III candidates, securing significant out-licensing partnerships for its lead assets across major markets in Asia, Europe, and North America, and generating clinical proof-of-concept for its platform. The company's strategy is to advance its most promising programs through late-stage trials to achieve regulatory milestones, while continuing to monetize its pipeline through regional partnerships and non-dilutive funding to drive towards commercialization.

Therapeutic Areas

Other Plaque Psoriasis Drugs